Disease or Syndrome
IRA round 2 begins as drugmakers sign on to price negotiation process with CMS
Myasthenic Syndromes, Congenital, Mediation, Prices, Medicare, Ira (eukaryote), drugmakers
Avidity’s Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment
Del-zota, Duchenne muscular dystrophy (DMD), RNA therapeutics, exon 44 skipping, dystrophin production, creatine kinase reduction, safety profile
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
eneboparatide, hypoparathyroidism, Phase III trial, Calypso study, Amolyt Pharma acquisition
Incyte’s oral HS drug hits study goals, but fails to excite investors
povorcitinib, JAK1 inhibitor, hidradenitis suppurativa, Phase 3 trials, efficacy, investor reaction, regulatory submission
AstraZeneca deepens cell therapy expansion with $1B EsoBiotec buyout
AstraZeneca, EsoBiotec, cell therapy, acquisition, ENaBL platform, in vivo cell engineering, oncology, autoimmune diseases
Curevo Secures $110M for Advanced Shingles Vaccine Development
Curevo Vaccine, amezosvatein, shingles vaccine, Series B funding, improved tolerability, Shingrix competitor
Orca’s cell therapy trounces traditional care in blood cancer phase 3, swimming into space’s ‘holy grail’
allogeneic hematopoietic stem cell transplant with purging, Leukemia, Myelocytic, Acute, Acute lymphocytic leukemia
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
entera, GLP-1/glucagon, first, Oral cavity, OPKO, Ownership, Entera
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
GLP-1 drugs, weight loss market, differentiation, competition, obesity treatment